

Cirrhosis in Over 16s: Assessment and Management Committee Meeting

Date: 16 March 2023

Location: Virtual Meeting via Zoom

Minutes: Final

| Committee members present: | |
|-----------------------------------|--------------------------------------|
| Caroline Jones (Chair) | Present for all items |
| Andrew Fowell | Present until partway through item 4 |
| Kathryn Jack | Present for all items |
| Fatema Jessa | Present for all items |
| Alastair O'Brien | Present from partway through item 1 |
| Emmanuel Wey | Present for items 1-4 |

| NICE in attendance: | | |
|----------------------------|---|-----------------------|
| Keona Bennett | Administrator, Guideline Development Team B | Present for item 1 |
| Chris Carmona | Technical Adviser, Guideline Development Team B | Present for all items |
| Lindsay Claxton | Technical Adviser, Health Economics, NICE | Present for all items |
| Bethan Dorsett | Medical Editor, NICE | Present for all items |
| Neil Drake | External Communications Manager, NICE (Observing) | Present for all items |
| James Jagroo | Technical Analyst, Guideline Development Team B | Present for all items |
| Clifford Middleton | Guideline Commissioning Manager, NICE | Present for all items |
| Adam O'Keefe | Project Manager, Guideline Development Team B | Present for all items |
| Magdalena Watras | Medicines Adviser, NICE | Present for all items |
| Yuanyuan Zhang | Technical Analyst, Health Economics | Present for all items |

| Apologies: | |
|-------------------|------------------------------|
| Vanessa Hebditch | Committee Member |
| Mathis Heydtmann | Committee Member |
| Imaad Rafiq | Committee Member |
| Benjamin Gregory | Resource Impact Lead, NICE |
| Wesley Hubbard | Information Specialist, NICE |

1. Welcome and introductions, Minutes of the previous meeting and Declaration of Interests

The Chair welcomed the committee members and attendees to the third meeting on the Cirrhosis in over 16s: assessment and management update. The committee members and attendees introduced themselves.

Minutes of the previous meeting required a correction to the list of attendees but were otherwise accepted as a true record.

The Chair confirmed that, for the purpose of managing conflicts of interest, the matter under discussion was Cirrhosis in over 16s assessment and management. The Chair then asked everyone to verbally declare any new interests that are not listed in the registry. The following new interests were declared:

| Attendee | Declaration | Classification | Action |
|---------------|--|-------------------|---|
| Andrew Fowell | Advisory board member for Dr Falk Pharma UK Ltd. Honorarium plus travel expenses to be received: Attendance at January 2023 meeting concerning autoimmune hepatitis. | Direct, financial | Non- specific interest No action needed other than process of open declaration |
| Andrew Fowell | Invitation from Dr Falk to speak at a regional event on autoimmune hepatitis. | Direct, financial | Non- specific interest No action needed other than process of open declaration |
| Emmanuel Wey | Private Clinical work in the capacity as a Consultant in Infection for HCA hospitals, the Cleveland clinic and The Doctors laboratory (TDL). | Direct, financial | Interest is specific but accounts for only approx. 10% of clinical work. No action needed other than process of open declaration |

The Chair and a senior member of the Developer’s team noted that the interests declared, nor those previously declared, did not prevent the attendees from fully participating in the meeting.

2. Review Question 1: What is the clinical and cost-effectiveness of non-selective beta-blockers (NSBBs), endoscopic variceal band ligation (EVL) or NSBBs plus EVL compared to each other for the primary prevention of bleeding in people with medium to large oesophageal varices due to cirrhosis?

The Chair introduced Chris Carmona (CC), who revisited and confirmed with the committee recommendations previously drafted for review question 1.

3. Review Question 3: What is the clinical and cost effectiveness of non-selective beta-blockers (NSBBs) for the primary prevention of decompensation in people with compensated cirrhosis?

The Chair introduced James Jagroo (JJ), who presented the committee with the clinical evidence supporting NSBB for the primary prevention of decompensation in people with compensated cirrhosis. JJ then took questions and comments from the committee. Yuanyuan Zhang (YZ) then presented the committee with the cost-effectiveness evidence identified before taking questions and comments. The committee discussed the evidence presented before drafting recommendations.

The Chair thanked JJ and YZ for their presentation and moved to the next item on the agenda.

4. Review Question 2: What is the clinical and cost-effectiveness of different antibiotics compared with each other, placebo or usual care for the primary prevention of SBP in people with cirrhosis and ascites?

The Chair reintroduced CC and YZ who presented the committee with the clinical and cost-effectiveness evidence for antibiotics for the primary prevention of SBP in people with cirrhosis and ascites. The committee asked questions and discussed the evidence presented before drafting recommendations.

The Chair thanked CC and YZ for their presentations and moved to the next item on the agenda.

5. Information For the Public (IFP) update

Bethan Dorsett (BD) outlined to the committee plans for the Information for the Public (IFP) to be provided alongside this guideline update.

The Chair thanked BD for her update and moved to the penultimate item on the agenda.

6. Equalities Impact Assessment

CC led a discussion on the Equality Impact Assessment for this update, specifically around the issues discussed at this meeting and whether new considerations needed to be made in light of the discussion.

The Chair thanked CC for this discussion and moved to the final item on the agenda.

7. AOB, summary and next steps

Adam O'Keefe (AO) advised that the post-consultation committee meeting is scheduled for to take place on 29 June and outlined next steps to consultation.

The Chair asked the committee if they had any other business, summarised the day, and thanked everyone for their contributions before closing the meeting.